Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial

Soo, Ross ARoss ASooHuat Tan, EngEngHuat TanHayashi, HidetoshiHidetoshiHayashiSeto, TakashiTakashiSetoCHIA-CHI LINOu, Sai-Hong IgnatiusSai-Hong IgnatiusOuKim, Dong-WanDong-WanKimLiu, GeoffreyGeoffreyLiuAbbattista, AntonelloAntonelloAbbattistaMartini, Jean-FrançoisJean-FrançoisMartiniHooi Wong, ChewChewHooi WongToffalorio, FrancescaFrancescaToffalorioSolomon, Benjamin JBenjamin JSolomon2024-01-122024-01-122022-0701695002https://scholars.lib.ntu.edu.tw/handle/123456789/638442To analyze the efficacy and safety of lorlatinib in Asian and non-Asian patients with pretreated anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC) from a phase 1/2 study.enAnaplastic lymphoma kinase; Asian; Lorlatinib; Non-small cell lung cancer; Tyrosine kinase inhibitorEfficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trialjournal article10.1016/j.lungcan.2022.05.012356609712-s2.0-85131633980https://api.elsevier.com/content/abstract/scopus_id/85131633980